Application of a new highly multiplexed amplicon sequencing tool to evaluate Plasmodium falciparum antimalarial resistance and relatedness in individual and pooled samples from Dschang, Cameroon
Overall, <i>Pf</i>-SMARRT is a robust tool for assessing parasite relatedness and antimalarial drug resistance markers from both individual and pooled samples. Control samples support that accurate genotyping as low as 1 parasite per microliter is routinely possible.
Authors
- Karamoko Niaré (ORCID: https://orcid.org/0000-0002-7406-9508)
- Alfred Simkin (ORCID: https://orcid.org/0000-0001-9408-0053)
- Samuel White (ORCID: https://orcid.org/0000-0002-3675-7545)
- Jeffrey A. Bailey (ORCID: https://orcid.org/0000-0002-6899-8204)
- Rhoel R. Dinglasan (ORCID: https://orcid.org/0000-0001-5433-8179)
- Jonathan B. Parr (ORCID: https://orcid.org/0000-0002-4465-9830)
- Sandrine E. Nsango (ORCID: https://orcid.org/0000-0002-0607-0881)
- Kevin Wamae (ORCID: https://orcid.org/0000-0001-7721-5534)
- Isabela Gerdes Gyuricza (ORCID: https://orcid.org/0000-0002-7969-1910)
- William J. Moss (ORCID: https://orcid.org/0000-0001-6579-3513)
- Jonathan J. Juliano (ORCID: https://orcid.org/0000-0002-0591-0850)
- Valery P. K. Tchuenkam
- Abebe A. Fola (ORCID: https://orcid.org/0000-0001-5392-2859)
- Christopher B. Tume (ORCID: https://orcid.org/0000-0001-6738-2937)
- Ashenafi Assefa (ORCID: https://orcid.org/0000-0002-0147-9362)
- Innocent Mbulli Ali (ORCID: https://orcid.org/0000-0002-1112-6376)
- Jacob M. Sadler
- Kyaw L. Thwai
Institutions
- University of North Carolina at Chapel Hill (US)
- Johns Hopkins University (US)
- Université de Dschang (CM)
- Brown University (US)
- Kenya Medical Research Institute (KE)
- University of Florida (US)
- Ethiopian Public Health Institute (ET)
- Centre Pasteur du Cameroun (CM)
Publication Details
- Journal
- Frontiers in Parasitology
- Published
- 2025-02-05
- DOI
- https://doi.org/10.3389/fpara.2024.1509261
- Citations
- 1
- Primary Topic
- Malaria Research and Control
- Type
- article
- Field-Weighted Citation Impact
- 1.88
Funders
- Bill and Melinda Gates Foundation
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases
- European and Developing Countries Clinical Trials Partnership